Gene Patent Stoush Heads to US Court
By Karen Barlow,
ABC News [Australia]
| 12. 08. 2011
The fight over human genes and whether they can be patented for medical research has gone to the US Supreme Court.
The American Civil Liberties Union and the Public Patent Foundation filed their appeal on Thursday, arguing genes are products of nature and cannot be sequestered by private companies.
The case concerns Myriad Genetics, a biotech company that holds patents on two genes that can help reveal susceptibility to breast and ovarian cancer.
There is concern their monopoly position stymies research and restricts patient access to tests and treatment, but the biotech sector and patent lawyers say there are safeguards.
[Audio: Action filed to invalidate gene patents (PM)]
ANU visiting fellow and intellectual property law consultant Luigi Palombi says if a company has a patent on a gene, it can control everything that happens with that gene.
"You can control its use in research, you can control its use in the development of a medicine, you can control its use in the use of a diagnostic, etc.," he said.
"And yet all you've done is discovered a link between a...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
